Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03549338
Title Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Symphogen A/S
Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU

No variant requirements are available.